Apple | Mobile |
---|---|
Business Dev & Design Entertainment | Social Media Tech Web Video |
Apple | Mobile |
---|---|
Business Dev & Design Entertainment | Social Media Tech Web Video |
Operates as a medical diagnostics company.
Year Established: | |
Funding: | |
Address: | Birmingham, AL 35211 |
Telephone: | 2147483647 |
Mobile: | |
Fax: | |
Mail: | |
Company URL: | http://www.atherotech.com |
NEW MEXICO
TERRITORY SALES MANAGER
We currently have a sales opportunity available in New Mexico. Our requirements are: bachelor's or equivalent work experience, minimum 3 years medical sales experience with relationships in the General Practice, Internal Medicine, Cardiovascular and Endocrinology call points (laboratory, pharma-cardiology, or cardiology device background is preferable), territory management experience in multi-state/city territory, a stable and proven sales work history, and past awards and recognition for your successful sales career. Must be experienced in Excel, Outlook, Word, and competent in IT connectivity (laptop/blackberry/internet savvy). Must have entrepreneurial knowledge and desire to "run your own business". If qualified and interested, please email your resume to jobs@atherotech.com. EOE
Risk Reduction (Patient) Educator
Responsible for the education, coordination, and provision of services to Atherotech disease management (DM) patients to assist in the promotion of health and in the prevention and control of CV disease. Assists in the identification, clinical management, and follow up of DM patients. Will be responsible for telephone consults, Web-based consults, and in-house services as needed in certain clinical offices. Bachelors Degree required. Minimum 5 years experience in executing, planning, and conducting programs in dietetics, nutrition, and/or lifestyle modification to reduce cardiovascular disease risk for the general and/or targeted public. Cardiology/lipid management/CDE/patient education experience preferred. Must be experienced in Excel, Outlook, Word, and competent in IT connectivity (laptop/blackberry/internet savvy). Based in the Birmingham, AL office. If qualified and interested, please email your resume to jobs@atherotech.com. EOE
Medical Science Consultant
To provide in-depth education to providers and Sales personnel about our VAP test and other cardiovascular risk makers performed by Atherotech. Our ideal candidate will have a Bachelor or Masters degree and a Nursing degree preferred; Knowledge of advanced lipid testing, (preferably VAP), and/or disease management programs desired. 5+ years clinical laboratory or nursing experience required (outpatient clinical experience a plus). You must have good organizational and business assessment skills. Must be experienced in Excel, Outlook, Word, and competent in IT connectivity (laptop/blackberry/internet savvy). This position requires about 60% travel. If qualified and interested, please email your resume to jobs@atherotech.com. EOE
Other Employment Opportunities
Thank you for your interest in our company. Currently we are not in search of additional team members/talent other than those listed above but we are growing our business every day. If another opening occurs, it will likely be that of a Territory Sales Manager. Our requirements for Territory Sales Manager are: bachelor's or equivalent work experience, minimum 3 years sales experience in lab background (pharma-cardiology or cardiology device background is acceptable), territory management experience in multi-state/city territory, a stable and proven sales work history, and past awards and recognition for your successful sales career. Must be experienced in Excel, Outlook, Word, and competent in IT connectivity (laptop/blackberry/internet savvy). Must have entrepreneurial knowledge and desire to "run your own business".
We consider it a compliment that you have chosen to visit our "Careers" page. We invite you to learn more about the importance of our comprehensive VAP test under "Patients". We wish you the best in your career search. If you would like your resume to be kept on file, please email it to jobs@atherotech.com. EOE
Compass Technology Partners
Kneeland Youngblood, M.D., Chairman of the BoardKneeland has extensive investment experience, having served from 1993 to 1999 on the board of the $100 billion Teacher Retirement system of Texas (TRS). In his capacity as a trustee, he was actively involved in hiring investment advisors, determining asset allocations and formulating investment/benefit policies. He served as chairman of the Fund's Real Estate Committee, where he directed a major restructuring of the $1.4 billion portfolio. He also served on the Board of Directors and developed direct private equity experience with the Texas Growth Fund, a $500 million private equity fund providing growth and expansion capital. Mr. Youngblood is also a Chairman of the board of the American Beacon Funds, a $20 billion investment affiliate of American Airlines. Mr. Youngblood's other board memberships include: Burger King, Starwood Hotels and Resorts and the City of Dallas Employee Retirement System. He is also a Director Emeritus of iStar Financial, a NYSE publicly traded REIT, and a Director Emeritus of the U.S. Enrichment Corporation. Mr. Youngblood is a founder of Pharos Capital Group. He is a graduate of Princeton University and the University of Texas Southwestern Medical School, and is a member of the Council on Foreign Relations.
Michael V. Mullen, President and CEOMike is an experienced operations and finance executive with substantial experience in the areas of laboratory sciences, finance and accounting. Mr. Mullen has been employed with the company for over six years in several different capacities. Prior to being appointed to President and Senior Executive Officer, he served as the company’s Chief Financial Officer and Controller where he managed finance, accounting, information technology, billing, reimbursement, and human resources, and he was heavily involved with the commercial side of the company’s business. He holds dual degrees in accounting and laboratory science.
Robert Shufflebarger, Chief Operating OfficerBob has more than 20 years of experience with life science and technology companies in areas of operations, finance, and marketing. He joined Atherotech in 2000 as one of the first 15 employees and led the scale-up of operations including increasing capacity more than 100 fold. Prior to Atherotech, Bob managed marketing and business development activities for Southern Research Institute, a contract research organization based in Birmingham, AL. He also worked at Southern Biotechnology Associates and at Avanti Polar Lipids, both privately held specialty chemical manufacturers in Birmingham. Bob holds a B.S. in Chemistry from Birmingham-Southern College and an MBA from Duke University.
Scott Rezek, Chief Commercial OfficerScott has lead sales and marketing initiatives for several industries including health care and technology. Prior to Atherotech, Scott managed a $300M global sales channel at Invitrogen, now Life Technologies (NASDAQ: LIFE), a global biotechnology tools company. Before Invitrogen, Scott worked at San Francisco-based retailer Williams-Sonoma and at Course Technology, a Boston-based publishing subsidiary of the Thomson Corporation. Scott started his professional career as an Account Executive providing account management and overall client support for clients like Sony and Digital/Compaq. He holds a bachelor's from the University of West Florida and a master's from Auburn University.
Rod VanWagoner, Vice President of SalesRod has over 20 years of experience in the laboratory industry with the majority of those years spent with Quest Diagnostics. He began his laboratory sales career as an account executive and held numerous sales and executive management positions with increased responsibility including Vice President of Sales and Marketing for a national diagnostic imaging company. Rod has extensive experience in laboratory operations management having managed several functional areas such as Information Technology, Client Services, logistics, and phlebotomy. He has extensive experience in negotiating managed care contracts as well as obtaining positive coverage policies for new and emerging diagnostic tests. Rod holds a B.A. in Business Administration and a green belt certification in Six Sigma.
Jennifer Mason, Vice President of Clinical OperationsMs. Mason is a member of the American College of Cardiology and the Preventive Cardiovascular Nurses Association. She is the lead author of a review paper, "Gamma Glutamyl Transferase: A Novel Cardiovascular Risk Biomarker" published in the journal, Preventive Cardiology. Mason is responsible for the disease management and clinician services departments at Atherotech, She is also responsible for developing programs to educate the public and health care professionals about Atherotech’s line of cardiometabolic tests.Ms. Mason comes to Atherotech with eight years experience in the advanced lipid profile market. As a clinician, she brings practical experience in cardiology and heart disease management with her to Atherotech.
Michael E. Cobble, M.D., Chief Medical OfficerMike is a board certified clinical lipidologist and fellow of the National Lipid Association. He runs a private practice in Salt Lake City where he has lived for more than 20 years and focuses on dyslipidemia, diabetes, cardiovascular diseases (CV), hypertension and primary care medicine. Cobble’s practice is also currently a referral clinic for the Harvard Bipolar Research Group encompassing mood and behavior care. He is the director of the Canyons Medical Center and on the board of directors for the Utah Healthy Living Foundation. Along with clinical patient care, Cobble is engaged with clinical research and medical education and is a member of the American Academy of Family Practice, the National Lipid Association, and the American Society of Hypertension. His published articles include topics on pathophysiology and treatment of diabetes. Cobble graduated with honors from the family practice program medical school/residency at The University of Utah School of Medicine. A large part of his practice involves cardiovascular risk assessments, vascular imaging, and the implementation of CV risk reduction strategies.
Eliot A. Brinton, M.D., Medical Advisory BoardDr. Brinton is Director of the Metabolism Section of Cardiovascular Genetics, Director of the LDL Apheresis Center, and Associate Professor at the University of Utah School of Medicine in Salt Lake City. Dr. Brinton is the Immediate-Past President of the Pacific Lipid Association and President of the Utah Atherosclerosis Society. He is a founding board member of both the National Lipid Association and of the American Board of Clinical Lipidology. He is also a fellow of the American Heart Association and of the National Lipid Association. Dr. Brinton is an Editor of Lipids Online, and an Assistant Editor of the Journal of Obesity, and serves on the editorial boards of the Journal of Clinical Lipidology, the Journal of Managed Care Pharmacy, and Clinical Lipidology. He has authored numerous original scientific studies, received many peer-reviewed research grants and held several leadership and advisory positions in scientific and governmental organizations as well as in consultation for the pharmaceutical industry.
Michael H. Davidson, M.D., F.A.C.C., F.A.C.P.,Medical Advisory BoardDr. Davidson is a Clinical Professor at the University of Chicago Pritzker School of Medicine, where he also serves as Director of Preventive Cardiology and Associate Vice Chairman for Continuing Medical Education. In addition, he is Founder, President, and Chief Executive Officer of the Chicago Center for Clinical Research, currently part of Radiant Research. Dr. Davidson earned his medical degree from The Ohio State University College of Medicine in Columbus. He then fulfilled his residency in internal medicine at Rush-Presbyterian-St. Luke’s Medical Center in Chicago, where he later completed a fellowship in cardiology.An active researcher, Dr. Davidson’s clinical research background encompasses both pharmaceutical and nutritional clinical trials. His extensive research on statins, novel lipid-lowering drugs, and nonpharmacologic risk factor reduction has established him as a key opinion leader in this area. His research also includes extensive work with food additives, dietary supplements, and health claim petitions to the US Food and Drug Administration. A prolific author and lecturer on lipid disorders, nutrition, and atherosclerosis, Dr. Davidson has coordinated more than 700 clinical trials in areas of preventive cardiology and published more than 200 articles for leading medical journals.Dr. Davidson is board-certified in internal medicine, cardiology, and clinical lipidology. He is a Fellow of the American College of Cardiology and the American College of Chest Physicians. In addition, he is President-elect (2009-2010) of the National Lipid Association. He was listed in America’s Top Physicians by the Consumers’ Research Council of America, 2004-2005, and named four times in The Best Doctors in America.
Prakash C. Deedwania, M.D., F.A.C.C., F.A.H.A., F.A.C.P., F.C.C.P.,Medical Advisory BoardDr. Deedwania is one of the most recognizable figures in the fields of hypertension, heart failure, lipid disorders, ischemic heart disease, rhythm disorders and preventive cardiology. He is Professor of Medicine at the University of California–San Francisco (UCSF) School of Medicine and is Chief of the Cardiology Division for the Veterans Administration Central California Health Care System (VACCHCS)/UCSF Program in Fresno. Dr. Deedwania is also Director of Cardiovascular Research for the UCSF Fresno–Central San Joaquin Valley Medical Education Program and Clinical Professor of Medicine at Stanford University in Palo Alto.Dr. Deedwania is a fellow of the American Heart Association, American college of Cardiology, American College of Chest Physicians and the American College of Physicians. He is a member of the American Thoracic Society, the American Federation of Clinical Research, the Council on Silent Myocardial Ischemia and Infarction, the International Society of Ambulatory Science and the New York Trudeau Society. He has served as Chair of the Executive Committee of the Laennec Society of the American Heart Association and he is currently President of the California Chapter of the American Society of Hypertension. Dr. Deedwania is Past President of the International Society for Holter and Noninvasive Electrocardiology (ISHNE). He is a member of several writing groups including the ACC/AHA Practice Guidelines on Chronic Stable Angina and Ambulatory ECG Monitoring. He also serves on the Practice Guidelines Committee of the Heart Failure Society of America. He recently served on the joint writing group of AHA/ADA/ACC for the position statement on intensive glucose control in patients with diabetes.Dr. Deedwania has authored numerous landmark clinical trials and has authored or co-authored more than 350 publications, including journal articles, book chapters and abstracts. Dr. Deedwania also serves on the editorial boards of numerous journals. He is an Associate Editor of the Annals of Noninvasive Cardiology and Senior Editor of Congestive Heart Failure and has served as Guest Editor for Journal of the American College of Cardiology. Dr. Deedwania lectures regularly both nationally and internationally.
Gary H. Gibbons, M.D.,Medical Advisory BoardDr. Gibbons is Director of the Cardiovascular Research Institute, Chairman of the Department of Physiology and a Professor of Medicine. He also serves as Program Director of the Center of Clinical Research Excellence and NIH T-32 Program in Cardiovascular Science. He earned his undergraduate degree from Princeton University and graduated magna cum laude from Harvard Medical School. He completed his residency and cardiology fellowship at the Harvard-affiliated Brigham & Women's Hospital in Boston. Dr. Gibbons has served as a board-certified cardiologist and clinician-scientist on the faculty at Stanford University (1990-1996) and Harvard Medical School (1996-1999) before becoming the founding Director of the Morehouse Cardiovascular Research Institute in July 1999. He has received numerous awards and honors including selection as: a Robert Wood Johnson Foundation Minority Faculty Development Awardee, a Pew Foundation Biomedical Scholar, an Established Investigator of the American Heart Association and an elected member of the National Academy of Sciences Institute of Medicine. Dr. Gibbons directs NIH-funded research in the fields of vascular biology, genomic medicine and the pathogenesis of vascular diseases. He has successfully garnered more NIH research grant funding than 95% of all investigators. The innovations derived from his research have resulted in the receipt of several US patents. His bibliography lists over 80 reviews and original reports in the fields of vascular biology, gene therapy, hypertension, atherosclerosis, genomics, health disparities research and cardiovascular medicine. Dr. Gibbons maintains a passionate commitment to expanding the gender and ethnic diversity of biomedicine as well as the elimination of health disparities. He is married with three children and resides in Atlanta, Georgia.
Gary H. Gibbons, M.D.,Medical Advisory BoardDr. Gibbons is the endowed Director of the Morehouse Cardiovascular Research Institute, a Professor of Medicine and Chairman of the Department of Physiology. He also serves as Program Director of the Center of Clinical Research Excellence and the NIH T-32 Training Program in Cardiovascular Science. Dr. Gibbons is a board-certified cardiologist with research training expertise in molecular vascular biology. He earned his undergraduate degree from Princeton University and graduated magna cum laude from Harvard Medical School in Boston. He completed his residency and cardiology fellowship at the Harvard-affiliated Brigham & Women's Hospital in Boston. His research mentors include Victor Dzau, Thomas Smith, A. Clifford Barger and Eugene Braunwald.He has been selected as a Robert Wood Johnson Foundation Minority Faculty Development Awardee, a Pew Foundation Biomedical Scholar, an Established Investigator of the American Heart Association (AHA) and was recently elected as member of the Institute of Medicine of the National Academy of Sciences. Dr. Gibbons was a member of the faculty at Stanford University (1990-1996) and Harvard Medical School (1996-1999) before becoming the founding Director of the Morehouse Cardiovascular Research Institute in July 1999. He serves on several editorial boards for journals in cardiovascular medicine as well as advisory boards and grant review committees for the NIH, Juvenile Diabetes Foundation and the AHA.Dr. Gibbons directs NIH-funded research in the fields of vascular biology, genomic medicine and the pathogenesis of vascular diseases and ranks in the top 5% in the receipt of NIH funding. The innovations derived from his research have resulted in the receipt of several US patents. His bibliography lists over 80 reviews and original reports in the fields of vascular biology, gene therapy, hypertension, atherosclerosis, genomics, health disparities research and cardiovascular medicine. Dr. Gibbons maintains a passionate commitment to expanding the gender and ethnic diversity of biomedicine as well as the elimination of health disparities.
-->
Peter H. Jones, M.D., F.A.C.P., F.N.L.A.,Medical Advisory BoardDr. Jones is an Associate Professor of Medicine in the Section of Atherosclerosis and Lipid Research at Baylor College of Medicine and the Methodist DeBakey Heart and Vascular Center in Houston, Texas. He is also Medical Director for The Methodist Weight Management Center in Houston. Dr. Jones is the lead study physician at Baylor for Look AHEAD, a multicenter, randomized, NIH-funded clinical trial studying lifestyle interventions to achieve and maintain weight loss, with a focus on type 2 diabetes.From 1989 to 1998, Dr. Jones was a member of the steering committee for the Air Force /Texas Coronary Atherosclerosis Prevention Study. He was member of the Interdisciplinary Council on Lipids and Cardiovascular Risk Intervention from 1990–1996, Chairman of the Morbidity and Mortality Review Committee, Lipoprotein Coronary Atherosclerosis Study (LCAS) (1993–1996), and is a Fellow of the Council on Clinical Lipidology (American Heart Association). Dr. Jones is board-certified in Clinical Lipidology, is a board member and former president (2005-2006) of the National Lipid Association, and a Fellow of the ACP and the NLA. Dr. Jones is also the author of numerous journal articles and books.
Richard B. Lanman, M.D.,Medical Advisory BoardDr. Lanman has broad experience in cardiovascular diagnostics testing. Currently, he is Chief Medical Officer at Veracyte, Inc., a molecular diagnostics company applying genomics to the diagnosis of various cancers. Dr. Lanman has worked extensively with physicians to adopt new medical technologies, especially minimally invasive diagnostics and novel primary and secondary prevention strategies.Dr. Lanman has authored several medical journal articles and abstracts in preventive cardiology and laboratory medicine. He has also published chapters in two medical textbooks. After serving as Chief of Quality at Kaiser Permanente (1987-1993), he became Medical Director of San Jose Medical Group (1993-1975), Chief Medical Officer at Atherotech Inc. (2000-2005) and then diaDexus Inc. (2005-2008).
Charles A. Reasner II, M.D., F.A.C.E., F.A.C.P., Medical Advisory BoardDr. Reasner is Medical Director at the Texas Diabetes Institute in San Antonio, Texas, and Professor of Medicine in the Department of Medicine, Division of Endocrinology, at the University of Texas Health Science Center (UTHSC) in San Antonio. He previously served as Chief of Clinical Endocrinology and Associate Professor of Medicine at Department of Medicine, Division of Endocrinology, UTHSC; Associate Program Director of the Internal Medicine Residency Program at UTHSC; Assistant Professor of Medicine, UTHSC Department of Medicine/Endocrinology; and Chief of the Endocrine & Metabolic Services and Associate Program Director of the Internal Medicine Residency Training Program, Department of Medicine, U.S.A.F. Medical Center Keesler at Keesler Air Force Base in Biloxi, Miss.Dr. Reasner is a fellow of the Royal College of Edinburgh. He is on the editorial board of the British Journal of Diabetes and Vascular Diseases and is Editor of the journal Practical Diabetology.
Peter P. Toth, M.D., Ph.D., F.A.A.F.P., F.I.C.A., F.A.H.A., F.N.L.A., F.C.C.P., F.A.C.C.,Medical Advisory BoardDr. Toth is in private practice at Sterling Rock Falls Clinic, a multispecialty physician group in Sterling, Ill., where he serves as Director of Preventive Cardiology. Dr. Toth is also Clinical Associate Professor in the Department of Family and Community Medicine at the University of Illinois and Southern Illinois University and is Chief of Medicine at the CGH Medical Center in Sterling.Dr. Toth is a member of the American Academy of Family Physicians, Illinois Academy of Family Physicians, American Association for the Advancement of Science, Vascular Biology Working Group, National Lipid Association, The Society of Teachers of Family Medicine, Alpha Omega Alpha Honor Medical Society, and Sigma Xi, The Scientific Research Society. He is also a member of the American College of Cardiology, American College of Chest Physicians, American Heart Association and the American Society of Hypertension. Dr. Toth serves on numerous editorial boards for lipidology, atherosclerosis and family care publications. He is Associate Editor of the Section on Lipids, Lipoproteins, Atherosclerosis, and Coronary Artery Disease in the Year Book of Endocrinology for Elsevier Publishing, Section Editor on Clinical trials and their Interpretations for Current Atherosclerosis Reports, and Editorial Chair of the Primary Care Section on the Biodiscussion and Biocritique Web sites. He is also a reviewer for more than twenty peer reviewed journals including Circulation, European Heart Journal, Diabetes/Metabolism Research and Reviews and the Journal of Clinical Lipidology. He has authored or edited 9 textbooks in preventive cardiology, lipidology, and hypertension and has 170 publications in journals and textbooks.He is a member of the American College of Cardiology's Council on Cardiovascular Disease Prevention and American Heart Association's Council on Atherosclerosis and Lipoproteins.